Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia

  • Reina Castillon, Judith
  • Pujol, Roser
  • López Sánchez, Marcos
  • Rodríguez Santiago, Benjamín
  • Aza-Carmona, Miriam
  • González, Juan Ramón
  • Casado, José Antonio
  • Bueren, Juan Antonio
  • Sevilla, Julián
  • Badell Serra, Isabel
  • Català, Albert
  • Belendez, Cristina
  • Dasi, María Ángeles
  • Díaz de Heredia, Cristina
  • Soulier, Jean
  • Schindler, Detlev
  • Pérez Jurado, Luis A.
  • Surrallés i Calonge, Jordi
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 x 10(-9)). Compared with 15 743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 x 10(-16)). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 x 10(-5)), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 x 10(-5)). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia

  • Reina Castillon, Judith
  • Pujol, Roser
  • López Sánchez, Marcos
  • Rodríguez Santiago, Benjamín
  • Aza-Carmona, Miriam
  • González, Juan Ramón
  • Casado, José Antonio
  • Bueren, Juan Antonio
  • Sevilla, Julián
  • Badell Serra, Isabel
  • Català, Albert
  • Belendez, Cristina
  • Dasi, María Ángeles
  • Díaz de Heredia, Cristina
  • Soulier, Jean
  • Schindler, Detlev
  • Pérez Jurado, Luis A.
  • Surrallés, Jordi
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 x 10(-9)). Compared with 15 743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 x 10(-16)). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 x 10(-5)), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 x 10(-5)). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detectable clonal mosaicism in blood as biomarker of cancer risk in Fanconi anemia

  • Reina-Castillón, Judith
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Surralles, Jordi|||0000-0002-4041-7519
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 × 10-9). Compared with 15?743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 × 10-16). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 × 10-5), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 × 10-5). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Individuals with FANCM biallelic mutations do no develop Fanconi anemia, but show risk for breast cancer, chemotherapy sensitivity toxicity and may display chromosome fragility

  • Catucci, Irene
  • Osorio, Ana|||0000-0001-8124-3984
  • Arver, Brita
  • Neidhardt, Guido
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Zanardi, Federica
  • Riboni, Mirko
  • Minardi, Simone
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Azzollini, Jacopo
  • Peissel, Bernard|||0000-0001-9233-3571
  • Manoukian, Siranoush
  • Vecchi, De, Giovanna
  • Casola, Stefano
  • Hauke, Jan|||0000-0001-8236-4075
  • Richters, Lisa
  • Rhiem, Kerstin
  • Schmutzler, Rita K.
  • Wallander, Karin
  • Törngren, Therese
  • Borg, Åke
  • Radice, Paolo|||0000-0001-6298-4111
  • Surralles, Jordi|||0000-0002-4041-7519
  • Hahnen, Eric|||0000-0002-1152-8367
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • Kvist, Anders
  • Benitez, Javier|||0000-0002-0923-7202
  • Peterlongo, Paolo|||0000-0001-6951-6855
PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer. Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS). FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations.MethodsBreast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes.ResultsFive cases homozygous for FANCM loss-of-function mutations were identified. They show a heterogeneous phenotype including cancer predisposition, toxicity to chemotherapy, early menopause, and possibly chromosome fragility. Phenotype severity might correlate with mutation position in the gene.ConclusionOur data indicate that biallelic FANCM mutations do not cause classical FA, providing proof that FANCM is not a canonical FA gene. Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene. Mutation testing of FANCM might be considered for individuals with the above-described clinical features.